Relapse timing is associated with distinct evolutionary dynamics in DLBCL

Diffuse large B-cell lymphoma (DLBCL) is cured in over 60% of patients, but outcomes are poor for patients with relapsed or refractory disease (rrDLBCL). Here, we performed whole genome/exome sequencing (WGS/WES) on tumors from 73 serially-biopsied patients with rrDLBCL. Based on the observation tha...

Descripción completa

Detalles Bibliográficos
Autores principales: Hilton, Laura K., Ngu, Henry S., Collinge, Brett, Dreval, Kostiantyn, Ben-Neriah, Susana, Rushton, Christopher K., Wong, Jasper C.H., Cruz, Manuela, Roth, Andrew, Boyle, Merrill, Meissner, Barbara, Slack, Graham W., Farinha, Pedro, Craig, Jeffrey W., Gerrie, Alina S., Freeman, Ciara L., Villa, Diego, Crump, Michael, Shepherd, Lois, Hay, Annette E., Kuruvilla, John, Savage, Kerry J., Kridel, Robert, Karsan, Aly, Marra, Marco A., Sehn, Laurie H., Steidl, Christian, Morin, Ryan D., Scott, David W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10029038/
https://www.ncbi.nlm.nih.gov/pubmed/36945587
http://dx.doi.org/10.1101/2023.03.06.23286584

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10029038/
https://www.ncbi.nlm.nih.gov/pubmed/36945587
http://dx.doi.org/10.1101/2023.03.06.23286584

Ejemplares similares